Your source for all Prime Therapeutics' April 2026 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for April 2026 will keep you informed on what’s trending now and trending clinical topics. 

---

Released April 7, 2026

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are DB-OTO (Regeneron) and pariglasgene brecaparvovec (Ultragenyx).

---

Released April 13, 2026

FDA Decisions Expected: May 2026

A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers golimumab, dexmethylphenidate hydrochloride (PVEK) and more.

---

Released April 16, 2026

Oncology Insights

Featuring commentary by Abby Kim, PharmD, BCOP, on developments in the oncology space, this installment reviews insights from the 2026 Oncology Drug Report, which offers a nuanced snapshot of how clinicians are engaging with innovation trends today. 

---

Released April 27, 2026

Trending Topics & Drug Approvals: April 2026

Prime covers hot topics and the latest specialty and traditional drug approvals. The latest edition covers Drug Safety Communications issued from the FDA for avacopan (Tavneos) and drugs containing carbidopa/levodop, which may cause vitamin B6 deficiency and associated seizures.

---

Released April 30, 2026

Quarterly Drug Approvals: April 2026 

Prime provides a quarterly drug pipeline report of anticipated new drugs, deep dives and indications for the following pipelines: traditional, specialty drugs, biosimilars, and gene and cell therapy. 

---

Released April 30, 2026

Quartely Drug Pipeline: April 2026

Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well-sourced on the drug pipeline. 

---

Looking for previous 2026 drug insights publications?

Simply click on the month to access past editions of our drug insights.

January 2026
February 2026
March 2026